TG Therapeutics, Inc. (TGTX): Gross Profit
$515.57M
Year ended 2025-12-31
$658.60M
Trailing 12 months to 2026-06-30
n/m
3-year compound annual growth
| Period ended | Gross Profit | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $515.57M | +77.5% | 2026-02-27, From 2025-01-01 |
| 2024-12-31 | $290.52M | +32.3% | 2026-02-27, From 2024-01-01 |
| 2023-12-31 | $219.53M | n/m | 2026-02-27, From 2023-01-01 |
| 2022-12-31 | $2.52M | -57.3% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $5.90M | n/a | 2024-02-29, From 2021-01-01 |
Gross Profit at similar companies
| Company | Year ended | Gross Profit | Change YoY |
|---|---|---|---|
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $515.57M | +77.5% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $205.94M | -5.8% |
| Insmed Inc (INSM) | 2025-12-31 | $483.49M | +73.9% |
| Organogenesis Holdings Inc. (ORGO) | 2024-12-31 | $366.30M | +12.1% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $599.89M | +65.6% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $212.16M | -24.6% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $644.39M | +10.4% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $356.06M | -4.8% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $576.66M | +8.7% |
Compare TGTX, OPK, INSM, ORGO side by side · Screen every company in Pharmaceutical Preparations ↗